Back to today’s briefing

Story perspectives

Leadership Shifts and Tragedies Shake Biotech Industry

3/18/2025

33 7

Summary

Story summary

Stoke Therapeutics is undergoing a leadership change as CEO Ed Kaye resigns, with Ian Smith stepping in as interim CEO. Meanwhile, Sarepta Therapeutics grapples with the tragic death of a patient tied to its gene therapy. In a brighter note, Arbor Biotechnologies secured $73.9 million for clinical trials, while FDA employees navigate tumultuous office returns. Additionally, NIH director Eric Green departs amid significant agency restructuring.

1 of 1

Story summary

Stoke Therapeutics is undergoing a leadership change as CEO Ed Kaye resigns, with Ian Smith stepping in as interim CEO. Meanwhile, Sarepta Therapeutics grapples with the tragic death of a patient tied to its gene therapy. In a brighter note, Arbor Biotechnologies secured $73.9 million for clinical trials, while FDA employees navigate tumultuous office returns. Additionally, NIH director Eric Green departs amid significant agency restructuring.